About EirGenix
About EirGenix
Vision and Mission
Milestones
Facilities and Capacities
Xizhi Facility
Zhubei Facility
Management Team
LEE-CHENG LIU
Klaus Martin
CHIH-JUNG CHANG
PORTIA LIN
HSIU-CHUAN YANG
SHANG-CHUNG JU
AE-NING LIN
HARK CHEN
Ywan-Feng Li
Videos
360-Degree Virtual Tour
News
EirGenix Activities
News
Events
Services
Cell Line Development
Process Development
Analytical & Quality Control
cGMP Manufacturing - Mammalian System
cGMP Manufacturing - Microbial System
ADC & Bioconjugates
Products & Pipeline
Commercial / Market-Available Products
(EIRGASUN®/HERWENDA®) Trastuzumab Biosimilar
Pipeline — Biologic Therapeutic Candidates
Supporting Products & Platforms
HRV3C Protease
CRM197
Investor
Financials
Monthly Revenue
2025
2024
2023
2022
2021
2020
2019
2018
Financial Reports
2024
2023
2022
2021
2020
2019
2018
Corporate Governance
Corporate Governance
Board of Directors
Internal Audit
Shareholder Services
Shareholders' Meeting
Investor Conference
Dividend Distribution
Market Observation Post System
Investor Relations & Media Contact
Stock Transfer Agent
ESG
ESG Overview
Recruiting
|
EN
|
繁中
0
Inquiry
EN
繁中
Contact us
0
Inquiry
About EirGenix
About EirGenix
Vision and Mission
Milestones
Facilities and Capacities
Xizhi Facility
Zhubei Facility
Management Team
LEE-CHENG LIU
Klaus Martin
CHIH-JUNG CHANG
PORTIA LIN
HSIU-CHUAN YANG
SHANG-CHUNG JU
AE-NING LIN
HARK CHEN
Ywan-Feng Li
Videos
360-Degree Virtual Tour
News
EirGenix Activities
News
Events
Services
Cell Line Development
Process Development
Analytical & Quality Control
cGMP Manufacturing - Mammalian System
cGMP Manufacturing - Microbial System
ADC & Bioconjugates
Products & Pipeline
Commercial / Market-Available Products
(EIRGASUN®/HERWENDA®) Trastuzumab Biosimilar
Pipeline — Biologic Therapeutic Candidates
Supporting Products & Platforms
HRV3C Protease
CRM197
Investor
Financials
Monthly Revenue
2025
2024
2023
2022
2021
2020
2019
2018
Financial Reports
2024
2023
2022
2021
2020
2019
2018
Corporate Governance
Corporate Governance
Board of Directors
Internal Audit
Shareholder Services
Shareholders' Meeting
Investor Conference
Dividend Distribution
Market Observation Post System
Investor Relations & Media Contact
Stock Transfer Agent
ESG
ESG Overview
Recruiting
|
EN
|
繁中
Search
×
Submit
×
Home
News
News
News
News
EIRGENIXは日本市場を拡大するために、日本の会社と長期供給契約の締結について
2021/03/02
More
EIRGENIX COMPLETES NEOADJUVANT TREATMENT AND SURGERY FOR LAST PATIENT IN PHASE III CLINICAL TRIAL
2020/11/08
More
VSTRIP® COVID-19 ANTIGEN RAPID TEST VALIDATED AND APPROVED IN INDIA!
2020/09/26
Vstrip® COVID-19 Antigen Rapid Test Validated and Approved in India!
More
EIRGENIX ACHIEVES THE THIRD MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT
2020/09/11
More
EIRGENIX RECEIVES 2020 BIOPROCESSING EXCELLENCE IN GREATER CHINA REGION AWARD!
2020/07/07
More
EIRGENIX ACHIEVES THE SECOND MILESTONE OF ITS BIOSIMILAR TRASTUZUMAB - LICENSING AGREEMENT
2020/03/09
More
EIRGENIX RECEIVES APPROVAL FROM JAPAN'S PMDA
2020/02/03
More
EIRGENIX'S REVENUE REACHES A RECORD HIGH IN JUNE
2019/07/10
More
EIRGENIX COLLECTS ITS INITIAL SIGNING FEE DAYS BEFORE ITS OFFICIAL IPO
2019/06/27
More
EIRGENIX INC. ANNOUNCES 3-DAY STOCK OPTION BIDDING AHEAD OF ITS LATE-JUNE IPO
2019/06/10
More
EIRGENIX HOLDS ITS PRE-IPO PRESS CONFERENCE
2019/05/29
More
EIRGENIX SIGNS TRASTUZUMAB BIOSIMILAR LICENSE AGREEMENT WITH NOVARTIS SANDOZ
2019/04/30
More
EIRGENIX AWARDED FOR ITS INNOVATION AT THE NATIONAL INDUSTRIAL INNOVATION AWARDS
2019/04/10
More
EIRGENIX, INC. WINS BEST BIOPROCESS EXCELLENCE IN TAIWAN AWARD
2019/02/27
More
EIRGENIX, INC. OFFICIALLY OPENS ITS NEW WORLD-CLASS COMMERCIAL MASS PRODUCTION FACILITY
2019/01/23
More
1
2
3